Skip to content

Gonococcal vaccine study in key populations in Kenya

Use of Bexsero immunization to detect cross-reactive antigens and anti-gonococcal antibodies in key populations in Kenya

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
PACTR
Registry ID
PACTR202009774604118
Enrollment
50
Registered
2020-09-03
Start date
2020-10-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gonorrhoea

Interventions

Sponsors

University of Oxford
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Minimum Age: 18 Years Maximum Age: 25 Years Sex: All Gender Based: No Accepts Healthy Volunteers: Yes Criteria: Inclusion Criteria: • Healthy male and female as assessed by a medical history, physical exam, and laboratory tests. • HIV-positive participants who are adherent to ART and virally suppressed (viral load <200 copies per ml) are considered healthy . • At least 18 years of age on the day of screening and will not reach 26th birthday on the day of the second vaccination (approximately 6 weeks after enrolment) • Willing and able to give informed consent for participation in the trial before any study-related procedures are performed. • Willing to donate blood samples for immunogenicity assessments.

Exclusion criteria

Exclusion criteria: Exclusion Criteria: • Any clinically significant acute or chronic medical condition that is considered progressive that, in the opinion of the Principal Investigator or designee, makes the volunteer unsuitable for participation in the trial • Pregnancy • Participation in another clinical trial (i.e. investigational HIV vaccine candidate), within the previous 3 months or expected participation during the study • Bleeding disorder diagnosed by a physician (e.g., factor deficiency, coagulopathy or platelet disorder that requires special precautions). • History of severe local or systemic reactogenicity to vaccines (e.g., anaphylaxis, respiratory difficulty, angioedema).

Design outcomes

Primary

MeasureTime frame
To assess if immunisation of individuals at risk for gonococcal infection with 4CMenB (Bexsero) elicits humoral and T cell cross-reactive responses against Ng.

Secondary

MeasureTime frame
To assess if immunisation of individuals at risk for gonococcal infection with 4CMenB (Bexsero) differs between HIV negative and positive participants.

Countries

Kenya

Contacts

Public ContactClara Agutu

Kenya Medical Research Institute CGMRC

CAgutu@kemri-wellcome.org+254720735000

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026